Trends in Cancer

Trends in Cancer is a leading reviews journal covering advances in cancer research and oncology published by Cell Press. Tweets by Editor Danielle Loughlin.

[Ansu Satpathy @Satpathology]

A holy grail for our lab has been tracking myeloid cells in human tumors in the same way that we track T and B cells with TCR/BCR.
@vincentzliu and @CalebLareau solved it!
We developed Mitotrek using scATAC-seq + mitochondrial DNA to do exactly this. Using Mitotrek, we find that new myeloid cells clones constantly infiltrate the tumor via circulating monocytes — and that their macrophage or dendritic cell fate is epigenetically programmed before tumor entry.
@10xGenomics @parkerici @CancerResearch @TheMarkFdn
https://t.co/Y37qbyw3F5

[TIAN TIAN @vicenttianfr]

Can ctDNA transform the management of biliary tract cancers? Our new @trendscancer forum paper outlines the promise, limitations, and path toward clinical implementation. Grateful to all collaborators who made this work possible. @PrecisionBTCnet @atuvibi
https://t.co/vNU7DazoKM

[Cancer Cell @Cancer_Cell]

Online Now: Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer https://t.co/weuodSESr5

[Trends in Cancer @trendscancer]

Be part of the Hallmarks of cancer legacy.
Join our distinguished keynote speakers Johanna Joyce @Joycelab & Faisal Mahmood @AI4Pathology in Sitges, Spain, November 1–3, 2026.

Abstract deadline: June 26, 2026

🔗https://t.co/lCv4t62UbC

@CellPressEvents #CSHallmarks2026

[Manel Esteller @ManelEsteller]

Interested in #DNAmethylation predictors of #cancer response to #immune checkpoint inhibitors, #targetedtherapy, and #chemotherapy? 🔎
Our recent Trends in Cancer @TrendsCancer @CellPressNews article summarizes the field : Don’t miss Table 1 for a comprehensive list!
https://t.co/qaR2UPWYri

[Eytan Ruppin, MD, PhD @EytanRuppin]

🚨 Out today in Cell! @CellCellPress

Path2Space: #AI that predicts spatial transcriptomics (ST) from H&E pathology, enabling spatial biomarker discovery in #BreastCancer at scale.

📄 https://t.co/GtrmH9zIDs

🧵1/8

[Dr. Patrick Hwu @PatrickHwuMD]

🧬 #ScienceSaturday

❓ What if cancer treatment could target not only tumor cells, but also the tumor’s stromal support: non-malignant, non-cancerous cells within the tumor microenvironment, that actively help cancer grow, spread, and resist treatment?

➡️ In a new study published in @CellCellPress, researchers identified uPAR, a cell-surface protein linked to aggressive tumor behavior, as a marker found on both solid tumor cells and the fibrotic, immune-suppressive environment that helps sustain them.

➡️ The team developed uPAR-targeted CAR T cells that attacked both tumor cells and their supportive stroma, leading to durable tumor regression across multiple cancer models, including metastatic disease.

➡️ They also found that senescence-inducing therapies, like chemotherapy, increased uPAR expression and made tumors even more vulnerable to CAR T cell treatment.

🌟 This dual-targeting strategy could help overcome some of the biggest barriers to CAR T therapy in solid tumors, including immune suppression and treatment resistance.

🔗 Read the study: https://t.co/dvHrEzUZ7F

@ZedaZhang @Aveline_Filliol @LoweLabMSKCC

[Trends in Cancer @trendscancer]

See what the organizers have to say about @CellPressEvents #CSHallmarks2026 and join them in Spain, Nov 1–3, 2026, to celebrate the convergence of basic and translational science, spark new connections, and shape the future of precision oncology.
https://t.co/kf2WYRrog5

[Anirban Maitra @Aiims1742]

Daraxonrasib in Previously Treated Advanced
RAS-Mutated #PancreaticCancer (Phase 1-2 study)
https://t.co/wCF8W95CxD
@RevMedicines @salmanpunekar

[Waggoner Lab @LabWaggoner]

Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer @jclinicalinvest @DrIgMelero @ClinicaNavarra
@CIMA_unav
https://t.co/xupcIBfw1o 🇪🇸

[Anirban Maitra @Aiims1742]

New @Cancer_Cell paper on mechanisms of resistance to @RevMedicines Daraxonrasib
Disrupted molecular glue complex drives RAS inhibitor resistance
https://t.co/lFzq41ki8p
18/40 genomic alterations in RAS pathway (👇🏽)
Recurrent RAS Y64 alteration attenuates tri-complex formation

[Aaron Newman Lab @AaronNewmanLab]

1/ Thrilled to share our new paper, out today in @Nature: "Non-invasive profiling of the tumour microenvironment with spatial ecotypes".

Paper (open access): https://t.co/EujZFqU7wi

[Christine A. Garcia, MD, MPH @christinemphmd]

New @Nature study: >50% of lung cancer metastases are seeded by other metastases, not the primary tumor. This "seeding from seeding" reveals a complex evolutionary cascade that allows cancer to colonize the body.
https://t.co/lYUyfRYOcP

[Manel Esteller @ManelEsteller]

Excited to share our latest @TrendsCancer @CellPressNews piece!
DNA #methylation is a key predictor of how patients respond to #cancer treatments, including #immunotherapy and targeted therapies.
#Epigenetics is becoming central to precision oncology!
https://t.co/PEpl7kriqJ

[Trends in Cancer @trendscancer]

Meet Trends Open: a new multidisciplinary, open-access reviews journal for commentaries and fresh perspectives across life, physical, health, sustainability, and applied sciences—welcoming early-career and established researchers. https://t.co/9rjgUT1K7r

[Anirban Maitra @Aiims1742]

From our @Nature paper, where we demonstrate profound molecular heterogeneity even between two synchronous liver metastases. This is the challenge of advanced #PancreaticCancer. Targeting truncal mutations like KRAS overcomes some of this recalcitrance.
https://t.co/JTKFdxYcMU

[Amin Aalipour @amin_aalipour]

With news of @KeloniaTx's acquisition by $LLY yesterday, a fitting time to share our Review on in vivo CAR-T engineering, out now in @trendscancer! We summarize state-of-the-art approaches to in vivo engineering and open questions still ahead. Full text link in comments!

[Trends in Cancer @trendscancer]

Reflect on 25 years of the Hallmarks of Cancer framework in this special issue from @CellCellPress https://t.co/nqS98w3ZjP

To continue the conversation, join us @CellPressEvents Hallmarks of Cancer, November 1–3, 2026, Sitges, Spain.
#CSHallmarks2026

[Laura Attardi @AttardiLaura]

Thrilled to share our new review article on #p53 and #plasticity in @trendscancer - p53: defender of lineage fidelity and foe of plasticity in cancer and regeneration @arati_rajeevan https://t.co/83q2cYFa9N

[Anirban Maitra @Aiims1742]

Two cancer associated fibroblast (CAF) papers in #PancreaticCancer
A: In @Cancer_Cell Reticular CAFs (rCAFs) facilitating tertiary lymphoid structures (TLS)
https://t.co/NQblRNScxI
B: In @CD_AACR senescent CAFs (senCAFs) promoting lymph node metastases
https://t.co/5j0NzfXvXc